retatrutide dosage trial just posted the biggest weight-loss numbers ever recorded for a drug — 28.3% (≈70 lb) average in Phase 3, with 45% of people hitting 30%+ loss, territory once reserved for bariatric Dosing Schedule for Retatrutide: Trial

A JAMA Network Open retrospective cohort study of 125,474 adults with overweight or obesity: Patients with T2DM: 46.5% discontinued by year one 64.1% discontinued by year two Patients without T2DM: 64.8% discontinued by year one 84.4% discontinued by year two Nearly 85% of patients without diabetes stopped taking GLP-1s within two years

Coverage Issues: Medicare For years, Medicare has been prohibited from covering weight loss drugs because of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, which explicitly bars coverage of drugs for weight loss

What is Tirzepatide weight loss

Hormones are fluctuating, sleep is often disrupted, and the demands of caring for a newborn can feel overwhelming